Clinicians are a step closer to being able to confidently and effectively use therapeutic drug monitoring to maximise the longevity and efficacy of anti-TNF agents for IBD patients. The Australian Inflammatory Bowel Disease Association (AIBDA), a branch of the Gastroenterological Society of Australia (GESA), is currently in the final stages of preparing consensus statements on ...
Guidelines will revolutionise the way gastroenterologists use biologics
By Amanda Sheppeard
20 Aug 2017